NovaBay Pharmaceuticals Receives Broadcast And Print Media Coverage

By February 23, 2009

San Francisco Bay Area KTVU-TV
News Segment And Genetic Engineering News
Article Highlight Company’s Unique Antimicrobial Compounds

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE Alternext US: NBY, http://www.novabaypharma.com), a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial and viral infections, has recently been featured in a segment on San Francisco Bay area’s KTVU-TV news and in an article in Genetic Engineering News.

The KTVU-TV segment highlights NovaBay’s lead compound in development, NVC-422, as a new way of killing bacteria without developing resistance, which is a growing problem with currently available antibiotics. The interview with Dr. Ron Najafi provides a tour of NovaBay’s lab facilities as well as an overview of the mechanism of action and therapeutic product opportunities for NVC-422. This novel product candidate is currently in human clinical trials for the treatment of a variety of infectious diseases. NVC-422 is based upon small molecules that white blood cells naturally produce to destroy microbes. NovaBay® has created and patented stable synthetic versions, known as the Aganocide® compounds, for topical uses; the goal is to take on all bacteria, including newer strains, which have grown resistant to antibiotics. For more information please visit http://www.irgnews.com/coi/NBY

The Genetic Engineering News article, titled “Case Study: Overcoming Antimicrobial Resistance: Pitting Topical, Nonantibiotic Agents against Systemic Antibiotic Overkill”, provides a thorough overview of available antibiotics, anti-infectives, human resistance to antibiotics, and NovaBay’s approach to killing bacteria using unique antimicrobial compounds. The piece can be found in its entirety at http://www.genengnews.com/articles/chitem.aspx?aid=2796.

About NovaBay® Pharmaceuticals

NovaBay® Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative non-antibiotic, antimicrobial product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay® has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens, without ever developing resistance. NovaBay® believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including resistant bacteria such as MRSA. NovaBay® has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. NovaBay® and Aganocide® AgaDerm™, AgaNase™, and NeutroPhase™ are trademarks of NovaBay® Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.

Forward-Looking Statements

This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay® disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Contact:

Investors:
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson  
Chief Financial Officer
510-899-8809
Contact Thomas Paulson

 

TOP